BTTX — Better Therapeutics Cashflow Statement
0.000.00%
HealthcareHighly SpeculativeMicro Cap
- $0.01m
- $7.72m
Annual cashflow statement for Better Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|
Period Length: | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG |
Status: | Final | Final | Final |
Net Income/Starting Line | -0.002 | -40.3 | -39.8 |
Depreciation | |||
Deferred Taxes | |||
Non-Cash Items | — | 10.4 | 1.83 |
Unusual Items | |||
Other Non-Cash Items | |||
Changes in Working Capital | 0.001 | -2.34 | 6.27 |
Change in Prepaid Expenses | |||
Change in Accounts Payable | |||
Change in Accrued Expenses | |||
Cash from Operating Activities | -0 | -30.8 | -28.9 |
Capital Expenditures | — | -1.07 | -1.18 |
Purchase of Fixed Assets | |||
Software Development Costs | |||
Cash from Investing Activities | — | -1.07 | -1.18 |
Financing Cash Flow Items | -0.062 | 62.3 | 0 |
Other Financing Cash Flow | |||
Net Issuance / Retirement of Stock | |||
Net Issuance / Retirement of Debt | |||
Cash from Financing Activities | 0.025 | 72.3 | 5.28 |
Beginning Cash Balance | |||
Ending Cash Balance | |||
Net Change in Cash | 0.025 | 40.4 | -24.8 |